- AnaptysBio Inc ANAB has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP).
- GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.
- The 16-week data were presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress.
- Data from 8 patients showed that 6/8 patients treated with imsidolimab monotherapy achieved the primary endpoint of response on the clinical global impression (CGI) scale at week 4 and week 16, without requiring rescue medication.
- Two of 8 patients were considered to have not met the primary endpoint because they dropped out of the trial before Day 29.
- Modified Japanese Dermatology Association severity index total score decreased on average by 29% at week 1, 54% at week 4, and 58% at week 16.
- Erythema with pustules decreased by 60% at week 1, 94% by week 4, and 98% by week 16.
- Imsidolimab was generally well-tolerated, and most treatment-emergent adverse events were mild to moderate in severity and resolved without sequelae.
- Phase 3 GEMINI-1 trial has been initiated after an end-of-Phase 2 meeting with the FDA.
- In addition to GPP, imsidolimab clinical development focuses on moderate-to-severe acne and moderate-to-severe hidradenitis suppurativa, with Phase 2 top-line data anticipated in these indications during 1H and 2H of 2022, respectively.
- Related: AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study.
- Price Action: ANAB stock traded lower by 0.18% at $27.54 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
